Widely used:Recently Viewed
Clear All$27.29
$1.41
(5.45%)
As on 30-Apr-2025 14:40EDT
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$1,507 Mln
P/E Ratio
--
P/B Ratio
3.54
Industry P/E
--
Debt to Equity
0.02
ROE
-0.1 %
ROCE
-9.6 %
Div. Yield
0 %
Book Value
6.18
EPS
-0.61
CFO
$-555.19 Mln
EBITDA
$-687.67 Mln
Net Profit
$-475.80 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Kiniksa Pharmaceuticals Ltd. Class A (KNSA)
| 37.97 | 18.19 | 32.09 | 47.12 | 43.01 | 6.91 | -- |
|
BSE Sensex
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|
|
Kiniksa Pharmaceuticals Ltd. Class A (KNSA)
| 17.09 | 27.27 | -33.39 | 59.76 | -60.63 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1.32 | 162.07 | -- | -140.92 |
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an... interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom. Address: 23 Old Bond Street, London, United Kingdom, WIS 4PZ Read more
CEO & Chairman of the Board
Mr. Sanj K. Patel
CEO & Chairman of the Board
Mr. Sanj K. Patel
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Kiniksa Pharmaceuticals Ltd Class A (KNSA) stood at $ 581 Mln as on 31-Dec-24
The share price of Kiniksa Pharmaceuticals Ltd Class A (KNSA) is $27.29 (NASDAQ) as of 30-Apr-2025 14:40 EDT. Kiniksa Pharmaceuticals Ltd Class A (KNSA) has given a return of 43.01% in the last 3 years.
Kiniksa Pharmaceuticals Ltd Class A (KNSA) has a market capitalisation of $ 1,507 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Kiniksa Pharmaceuticals Ltd Class A (KNSA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Kiniksa Pharmaceuticals Ltd Class A (KNSA) and enter the required number of quantities and click on buy to purchase the shares of Kiniksa Pharmaceuticals Ltd Class A (KNSA).
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom. Address: 23 Old Bond Street, London, United Kingdom, WIS 4PZ
The CEO & director of Mr. Sanj K. Patel. is Kiniksa Pharmaceuticals Ltd Class A (KNSA), and CFO & Sr. VP is Mr. Sanj K. Patel.
There is no promoter pledging in Kiniksa Pharmaceuticals Ltd Class A (KNSA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
10
|
| Kiniksa Pharmaceuticals Ltd. Class A (KNSA) | Ratios |
|---|---|
|
Return on equity(%)
|
-9.85
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-10.21
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Kiniksa Pharmaceuticals Ltd Class A (KNSA) was $0 Mln.
